|
Categories
Pharmaceutical Company
Pharmaceutical Sales
Pharmaceutical
Distributor
Pharmaceutical
Preparation
Pharmaceutical
Jobs
Pharmaceutical
Industry
Pharmaceutical
Drug
Pharmaceutical
Sales Jobs
Pharmaceutical
Product
Pharmaceutical
News
Pharmaceutical
Research
Pharmaceutical
Manufacturer
Pharmaceutical Sales
Rep
Pharmaceutical
Sales Resume
Pharmaceutical
Online
Pharmaceutical
Marketing
Pharmaceutical
Dictionary
Pharmaceutical
Recruiter
Pharmaceutical
Supply
Pharmaceutical
Technology
Pharmaceutical
Advertising
Pharmaceutical
Schools
Companies
Pfizer Pharmaceutical
Wyeth Pharmaceutical
Watson Pharmaceutical
Merck Pharmaceutical
Roche Pharmaceutical
King Pharmaceutical
Teva Pharmaceutical
Aventis
Pharmaceutical
Novartis
Pharmaceutical
Forest
Pharmaceutical
Tap
Pharmaceutical
Shire
Pharmaceutical
Mayne
Pharmaceutical
Millennium
Pharmaceutical
Lilly
Pharmaceutical
Mylan
Pharmaceutical
Kos
Pharmaceutical
Takeda
Pharmaceutical
Endo
Pharmaceutical
Janssen
Pharmaceutical
Barr
Pharmaceutical
Abbott
Pharmaceutical
Reliant
Pharmaceutical
Solvay
Pharmaceutical
Amylin
Pharmaceutical
Vertex
Pharmaceutical
Osi
Pharmaceutical
Bayer
Pharmaceutical
Voyager
Pharmaceutical
Mcneil
Pharmaceutical
Boehringer
Ingelheim
Astra
Zeneca Pharmaceutical
Glaxosmithkline
Pharmaceutical
Novo Nordisk
Pharmaceutical
3m
Pharmaceutical
Eli
Lilly Pharmaceutical
Elan Pharmaceutical
Ivax
Pharmaceutical
Search engines:
Google
Lycos
AltaVista
Yahoo
Mirago
Ask
Teoma
Excite |
|
|
|
Amylin Pharmaceuticals
 Amylin Pharmaceuticals
Amylin Pharmaceuticals is a
biopharmaceutical company committed to improving lives through the discovery,
development and commercialization of innovative medicines.
The company
was founded in 1987 on the discovery of a hormone, amylin, produced by the same
beta cells of the pancreas that make insulin. Since then, Amylin has built a
strong foundation on research and development. Amylin's scientists are
primarily focused on investigating the potential utility of new peptide hormone
candidates. The company has amassed significant research and clinical expertise
in metabolic medicine including the areas of diabetes, obesity and
cardiovascular disease.
By "Challenging Science," Amylin challenges
conventional thinking to create innovative approaches to the discovery,
development and commercialization of novel therapies for metabolic diseases.
Amylin's approach and dedication are rooted in the belief that they will be
"Changing Lives" for millions of people - not only with the drugs currently in
late-stage development, but also with their pipeline of future
therapies.
Amylin Research
Amylin’s research
organization challenges the boundaries and processes of traditional drug
research by following paths designed by nature. We create innovative approaches
to the discovery and development of novel therapies for metabolic diseases such
as diabetes, obesity and cardiovascular diseases by leveraging our deep
understanding of the chemistry and integrated biology of peptide
hormones.
The Amylin Discovery Engine
Amylin’s drug
discovery engine supports a sustainable pipeline by leveraging the advantages
inherent in peptide hormones, such as low toxicology risks and their track
record as commercially successful drugs. Amylin has compressed the discovery
timeline through the early use of animal models and efficient initiation of
clinical studies.
Amylin has developed a proprietary library of novel
synthetic polypeptides to identify and characterize novel activities of both
known peptides as well as new peptides not yet on the map. We believe the depth
of this peptide library is unmatched in the biotech and pharmaceutical
industries and creates substantial value as a proprietary asset.
The
Amylin Formula
Rather than the widely accepted target-first
approach, where libraries of uncharacterized compounds are screened against a
known, understood, or validated drug target, Amylin identifies therapeutic
activity and characterizes the peptide drug lead independent of determining a
target. Because the industry has learned through failure that target
specificity is not a guarantee of success, Amylin is able to apply knowledge of
function and therapeutic action before chemical and biological optimization.
Comprehensive early understanding of lead peptide biology and its safety
profile provides greater opportunity for success in clinical
development.
Amylin Therapeutic focus
Amylin is dedicated
to improving lives through the discovery, development and commercialization of
innovative medicines for the treatment of diabetes, obesity and cardiovascular
disease.
Amylin further information
http://www.amylin.com/
|
|
|
|
|
